Please login
Bulletins

Posted: Thursday, May 12, 2011

NASCOLA-ISLH Meeting (May 2011 in New Orleans) Was a Success!

 
NASCOLA has a very successful 2011 partnership meeting with the International Society of Laboratory Hematology (ISLH) this May.  NASCOLA helped plan the coagulation and haemostasis content of the meeting, and it also held its 2011 General Membership meeting.  To quote many attendees "This was our very best meeting ever". Members are welcome to view the posted abstracts and powerpoint presentations from this year`s meeting.

There is an opportunity for NASCOLA to repeat the success of its 2011 partnership meeting when the ISLH meeting will be held in Toronto, May 10-12, 2013 - Save the Date!

Next year, NASCOLA will be one of the hosts of the very first, North American Summit meeting on Haemostasis and Thrombosis in Chicago, May 3-5, 2012 - Save The Date!
 

Posted: Thursday, February 17, 2011

Aniara Diagnostica LLC offers chance to win a trip to ISTH 2011

 

WING Your Way to Kyoto for ISTH 2011     

 

Aniara Diagnostica LLC is offering an all expenses paid trip for a lucky winner to the XXIII Congress of the International Society on Thrombosis and Hemostasis (ISTH) and 57th Scientific Standardization Committee Meeting in Kyoto Japan, July 23-28, 2011. The prize includes airfare to Kyoto, ISTH meeting registration fees, lodging, and food; the value not to exceed $15,000.

 

Eligible contestants must work in the field of Hemostasis and Thrombosis as a practicing laboratory technologist or academia researcher. To enter: Aniara | ISTH 2011 Contest, visit our website at www.aniara.com or visit us on Facebook.

 

Kyoto is one of Japan's oldest and most historic cities, offering an intriguing cultural blend of both modern and traditional Asia. We hope to see you there!

 

LAST DAY TO ENTER IS MARCH 31, 2011. Winner will be notified by April 15!

 

Posted: Thursday, February 17, 2011

Dabigatran controls and calibrators available from Aniara Diagnostica LLC

 

Dabigatran is the active component of the oral anticoagulant prodrug, Dabigatran Etexilate and in specific situations or in emergency situations warrants monitoring.

 

Aniara Diagnostica LLC offers Dabigatran Plasma Calibrators (A222801) and Control Plasma (A224701) to be used in conjunction with the Hemoclot Thrombin Inhibitor Kit (ACK002K and ACK002L) to assist the laboratory in the set up of the dabigatran assay. Since dabigatran etexilate (Praxda) is a pro-drug controls cannot be made in the lab.

 

Dabigatran Plasma Calibrators enable the creation of a calibration curve for the measurement of Dabigatran in plasma, and are titrated and optimised for use with the HEMOCLOT Thrombin Inhibitors anti-IIa clotting assay. This assay is designed for the quantitative measurement of Hirudin, Argatroban, and other current and future direct thrombin inhibitors in plasma by their direct antithrombin activity. The calibrators and controls are currently being submitted to the FDA for approval using the HEMOCLOT Thrombin Inhibitor Kit.  If the dabigatran calibrators are used with other kits, results can vary according to the assay reactivity and its standardization.

 

For more information please contact Aniara Diagnostica LLC at info@aniara.com, visit our website at www.aniara.com or www.dabigatrantesting.com

 

 

Posted: Thursday, February 17, 2011

Have lunch on Aniara Diagnostic LLC - Enter the lunch lottery

 

Clinical coagulation laboratories have an opportunity to have lunch on Aniara Diagnostic LLC.  By entering a monthly lottery, you have a chance to win lunch for your lab. Winners are selected at random and if your location is selected, Aniara will contact you to make all of the necessary arrangements. Enter often to increase the odds of winning lunch for you and your colleagues. Set up a lunch and learn or just have a nice lunch with fellow co-workers.

 

For those clinical laboratories that may not accept lunch due to institutional policies, Aniara offers an alternative. If you enter and select the WIN & GIVE option, you’ll be entered for a chance to donate $300 to a chosen charity.

 

Entrants must represent a Clinical Corporation or Special Coagulation Laboratory to be eligible. To enter and for a list of terms and conditions and complete contest rules: Aniara | Lunch Lottery Terms & Conditions

 

Posted: Wednesday, January 19, 2011

New Products from r2 Diagnostics

 

r2 Diagnostics has announced the introduction of new venom screen and confirm reagents for detection of lupus anticoagulants.

 

LupoTek DetecTin VL and CorrecTin VL test kits are qualitative tests intended to aid in the detection of lupus anticoagulants (LA) in citrated plasma.  LupoTek DetecTin VL and LupoTek CorrecTin VL use Vipera lebetina venom (VLV) rather than Vipera russelli (Russell’s Viper) venom (RVV). Using VLV is more eco-friendly than using RVV, as the VL viper is less endangered than the VR viper.

 

Vipera lebetina venom (VLV), like Russell's viper venom (RVV), will directly activate Factor X without requiring Factor VII. The activated Factor X in conjunction with Factors V, II, calcium ions and phospholipid will generate thrombin which converts fibrinogen to fibrin, producing a clot in the test system.

 

LupoTek DetecTin VL, the low phospholipid reagent, is designed as the screening reagent to detect a prolongation of the clotting time. LupoTek CorrecTin VL is the high phospholipid reagent that neutralizes the LA and corrects the clotting time to normal, confirming the presence of a Lupus Anticoagulant.

 

LupoTek DetecTin VL and CorrecTin VL demonstrated sensitivity of 100% and specificity of 100% with a normalized ratio of 1.30 in a 122 patient cutoff study.

 This reagent combination also demonstrated 98% positive agreement, 96% negative agreement, and 97% overall agreement with dRVV reagents in a 155 patient, multisite study.

 

 

LupoTek KCT - Kaolin Clotting Time - is also intended to assist in the detection of lupus anticoagulants in citrated plasma, and recently gained FDA 510(K) clearance. The LupoTek KCT is a modified activated partial thromboplastin time (APTT) reagent without any added phospholipids.  The KCT is exquisitely sensitive to LA, and has been reported as the most sensitive test for LA. (Lesperance B, David M, Rauch J, Infante-Rivard C, Rivard GE: Relative sensitivity of different tests in the detection of low titer lupus anticoagulants. Thromb Haemost 1988 Oct 31;60(2):217-219)

 

In a study of 180 patients, the KCT demonstrated 100% agreement in previously diagnosed LA patients and  59% agreement in those patients who were determined to have no evidence of  LA as compared to an APTT using a LA-sensitive reagent,  which demonstrated  87% agreement in the LA- positive group and 15% agreement in the LA-negative group.

 

The LupoTek KCT is suitable for use on most semiautomated and automated coagulation analyzers.

 

Posted: Monday, November 29, 2010

NASCOLA Publications

 
NASCOLA is active in publishing in and contributing to several journals.  These publications include test of the month articles, results of NASCOLA surveys, and information on proficiency data.  The following is an all inclusive listing on published articles to date.

Publications of NASCOLA Surveys, Proficiency Data, or “Test of the Month” articles:

 

1.      Hayward CM,  Moffat KA, Raby A, Israels S, Plumhoff E, Flynn G, Zehnder JL.  Development of North American Consensus for Medical Laboratories That Perform and Interpret Platelet Function Testing Using Light Transmission Aggregometry.  Am J Clin Pathol 2010; 134:955-963.    

2.      Khor B, Van Cott EM.  Laboratory tests for antithrombin deficiency. Am J Hematol 2010 (Dec); in press.

3.      Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EIB. Lupus anticoagulant testing: performance and practices by North American clinical laboratories.  Am J Clin Pathol 2010 (Nov); 134: 764-773.

4.      Otis SA, Zehnder JL.  Heparin-induced thrombocytopenia: Current status and diagnostic challenges.  Am J Hematol, 2010 (Sep); 85(9): 700-706

5.      Ledford-Kraemer MR.  Analysis of von Willebrand Factor (VWF) Structure by Multimer Analysis.  Am J Hematol, 2010 (May); 85(5): 510-514.  

6.      Smock KJ, Rodgers GM.  Laboratory evaluation of aspirin responsiveness.  Am J Hematol 2010; May;85(5):358-60. 

7.      Khor B, Van Cott EM.  Laboratory tests for protein C deficiency.  Am J Hematol 2010; Jun;85(6):440-2.

8.      Castellone D, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010 Mar;85(3):185-187.

9.      Van Cott EM. All that glitters is gold?  Am J Hematol. 2010 Apr;85(4):223-224.

10.  Smock KJ, Rodgers GM.  Laboratory identification of lupus anticoagulants.  Am J Hematol 2009 Jul;84(7):440-442.

11.  Nichols WL, Rick ME, Ortel TL, Montgomery RR, Sadler JE, Yawn BP, James AH, Hultin MB, Manco-Johnson MJ, Weinstein M.  Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol. 2009 Jun;84(6):366-370.

12.  Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.  Am J Clin Pathol. 2009 Apr;131(4):552-558. 

13.  Hayward CPM, Moffat KA, Spitzer E, Timleck M, Plumhoff E, Israels SJ, White J. Results of an external proficiency testing exercise on platelet dense granule deficiency testing by whole mount electron microscopy. Am J Clin Pathol. 2009 May;131(5):671-675.

14.  Moffat KA, Ledford-Kraemer MR, Plumhoff EA, McKay H, Nichols WL, Meijer P, Hayward CPM. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost. 2009 Jan;101(1):178-184.

15.  Cattaneo M, Hayward CPM, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009;7:1029.

16.  Verhovsek M, Moffat KA, Hayward CP. Laboratory testing for fibrinogen abnormalities.  Am J Hematol. 2008 Dec;83(12):928-931.

17.  Abstracts: 2nd Mayo/NASCOLA Coagulation Testing Quality Conference. Am J Hematol 2008(Dec);83(12):941-948.

18.  Price EA, Hayward CP, Moffat KA, Moore JC, Warkentin TE, Zehnder JL. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost. 2007 Dec;98(6):1357-1361. 

19.  Olson JD, Preston FE, Nichols WL.  External Quality Assurance in Thrombosis and Hemostasis: An International Perspective. Semin Thromb Hemost 2007;33:220–225.

20.  Van Cott EM, Ledford-Kraemer M, Meijer P, Nichols WL, Johnson SM, Peerschke EIB.  Protein S: An Analysis of the North American Specialized Coagulation. Laboratory Association Proficiency Testing.  Am J Clin Pathol 2005; 123: 778-785.

21.  Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP.  Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost. 2005 Mar;93(3):549-553.

 

 

 

 

 

Posted: Tuesday, January 26, 2010

r2 Diagnostics offers NASCOLA member laboratories opportunity for collaboration

 

The US Food and Drug Administration’s 510(k) Substantial Equivalence submission process has recently begun asking in vitro diagnostics companies to provide more multi-lab data for specific reagent-instrument combinations as part of the data requirement for reagent submissions.  r2 Diagnostics is seeking partners in the clinical coagulation laboratory community who are interested in participating in such cross‑laboratory method comparison and method precision studies.

 

r2 is currently looking for laboratories using the Stago STA Compact and the ACL ELITE.  Interested laboratories should email Marc Goldford, with the name and phone number of their contact person, and he will reply with the details of our upcoming studies.

 

Contact information follows:

 

Marc Goldford, Director R&D

r2 Diagnostics, Inc.

1801 Commerce Drive

South Bend, IN 46628

Email:   marc@r2diagnostics.com

Voice:  574-288-4377

Fax:     574-288-2272

Web:   http://www.r2diagnostics.com/

 

Posted: Friday, December 18, 2009

2009 Coagulation/Hemostasis Technologist Award for Excellence

 

Aniara recently announced the recipient of the 2009 Coagulation/Hemostasis Technologist Award for Excellence.  Marilyn Johnston, from NASCOLA member laboratory,  Hemostasis Reference Laboratory in Hamilton, Ontario, Canada, is the winner of this generous award.  She was nominated in 3 separate letters from peers and was ultimately chosen by the CHTAE selection committee. 


In addition to being recognized nationally and internationally for her contributions to the field of hemostasis, the committee was most impressed with her work in mentoring others.  Quotes from the nomination letters include:

 

“Marilyn has acted as mentor for a number of technologists and research fellows and continues to share her knowledge and expertise in the area of hemostasis and thrombosis. “

 

 “Marilyn encouraged her team to take the extra time and use the technology needed to dissect complex cases. She would bring in new technology when needed, adapt old technology if applicable and make up new technology if none existed. Many of the technologists working for Marilyn were inspired to achieve advanced certification by her mentorship.”

 

“Marilyn exemplified true entrepreneurial leadership in the creation and development of a unique hemostasis specialty testing laboratory for the purpose of aiding young medical researchers and laboratorians in the development of their career interest especially in the area of anticoagulation testing which continues to enhance the knowledge and understanding of hemostasis. Her contributions to the education of technologists, medical students and residents in the area of hemostasis are significant as exemplified by the numerous journal publications, scientific reviews, book chapters and speaking engagements.”

 

Our congratulations to Marilyn for a much-deserved award and recognition.  Thank you to Aniara (an Associate NASCOLA Member) for initiating and continuing to support this wonderful award. 

 

Posted: Friday, November 20, 2009

NASCOLA members contribute to “Test of the Month” feature in the American Journal of Hematology

 

NASCOLA members, Kristi Smock and George Rodgers, have published a “Test of the Month” feature in the American Journal of Hematology on lupus anticoagulant testing.  The abstract is below, along with a link to the full article for NASCOLA members who are subscribers to the Wiley InterScience publications site:

 

Laboratory identification of lupus anticoagulants.

 

Lupus anticoagulants (LA) are acquired autoantibodies that can cause antiphospholipid syndrome. LAs prolong phospholipid-dependent coagulation tests, acting as nonspecific inhibitors that are neutralized in the presence of excess phospholipid. However, there is no gold standard test and the testing is influenced by a number of variables. This article summarizes laboratory testing for LAs, with particular focus on technical issues and limitations of testing.

 

Am J Hematol. 2009 Jul;84(7):440-2.


The link to the full text for subscribers
 

Posted: Friday, November 20, 2009

NASCOLA members publish in American Journal of Clinical Pathology: Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.

 

NASCOLA members, Ellinor Peerschke, Donna Castellone, Marlies Ledford-Kraemer, and Elizabeth Van Cott, along with Piet Meijer from ECAT, have published an analysis of factor VIII inhibitors as assessed by NASCOLA proficiency testing.  The abstract is below, along with a link to the full article for NASCOLA members who are subscribers to Am J Clin Pathol:

 

Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.

Quantification of inhibitory antibodies against infused factor VIII (FVIII) has an important role in the management of patients with hemophilia A. This article summarizes results from the largest North American FVIII inhibitor proficiency testing challenge conducted to date. Test samples, 4 negative and 4 positive (1-3 Bethesda units [BU]/mL), were distributed by the ECAT Foundation in conjunction with the North American Specialized Coagulation Laboratory Association and analyzed by 38 to 42 laboratories in 2006 and 2007. Whereas laboratories were able to distinguish between the absence and presence of low-titer FVIII inhibitors, the intralaboratory coefficient of variation was high (30%-42%) for inhibitor-positive samples, and the definition of lower detection limits of the assay was variable (0-1 BU/mL). Most laboratories performed the Bethesda assay with commercially supplied buffered normal pooled plasma in a 1:1 mix with patient plasma. These data provide information for the development of consensus guidelines to improve FVIII inhibitor quantification.


Am J Clin Pathol. 2009 Apr;131(4):552-8.


The link to the full text for subscribers
 

Posted: Saturday, July 11, 2009

NASCOLA meeting during ISTH

 
NASCOLA thanks its members who attended the NASCOLA Scientific Luncheon Meeting at the ISTH in Boston - the meeting was extremely well attended. The presentors did a superb job of updating the membership on the latest NASCOLA research.
 

Posted: Thursday, June 11, 2009

NASCOLA Member Publication III

 

 

NASCOLA member, William L. Nichols contributed to the "Test of the Month" feature in the American Journal of Hematology.  Following is the abstract of the publication and a link to the full text for those NASCOLA members who are subscribers to the Wiley InterScience publications site.

Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of the 2008 NHLBI/NIH guidelines


Von Willebrand factor (VWF) mediates blood platelet adhesion and accumulation at sites of blood vessel injury, and also carries coagulation factor VIII (FVIII) that is important for generating procoagulant activity. Von Willebrand disease (VWD), the most common inherited bleeding disorder, affects males and females, and reflects deficiency or defects of VWF that may also cause decreased FVIII. It may also occur less commonly as an acquired disorder (acquired von Willebrand syndrome). This article briefly summarizes selected features of the March 2008 evidence-based clinical and laboratory diagnostic recommendations from the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel for assessment for VWD or other bleeding disorders or risks. Management of VWD is also addressed in the NHLBI guidelines, but is not summarized here. The VWD guidelines are available at the NHLBI Web site http://www.nhlbi.nih.gov/guidelines/vwd). Am. J. Hematol. 84:366–370, 2009.



The link to the full text for subscribers: 

 

Updated: Tuesday, June 02, 2009

Posted: Tuesday, February 03, 2009

NASCOLA Recognition Award 2009

 

NASCOLA is pleased to announce that Dr. James White was awarded the first NASCOLA Recognition Award Program at the 2009 NASCOLA/Mayo Clinic Meeting.  Dr. White received this recognition for his life long contributions to laboratory assessment of platelet ultrastructure, including his pioneering work on using electron microscopy in the diagnosis of platelet disorders. He is widely recognized as a world leader in our field. He has made sentinel discoveries on the structural defects in platelets from individuals with platelet disorders.

The NASCOLA recognition award is a nonmonetary prize, awarded every two years, to recognize outstanding achievements and contributions of members. We encourage you to begin thinking about nominations for 2011. There are two award categories: one at the technologist level, and the other at the physician/scientist level.
 Nominations should include a letter or letters of recommendation, that outline why you feel an individual should be nominated for a recognition award.  Multiple letters for nominees are welcome – at least one must be from a NASCOLA member.  Please note, to be eligible for a recognition award, the nominees must be affiliated with an active NASCOLA institutional membership. In early 2011, we be welcoming your nominations again.

We congratulate Dr. White on his achievements!

 

Posted: Friday, January 16, 2009

NASCOLA Member Publications II

 

NASCOLA members, Madeleine Verhovsek, Karen A. Moffat, and Catherine P.M. Hayward contributed the the "Test of the Month" feature in the American Journal of Hematology.  Following is the abstract of the publication and a link to the full text for those NASCOLA members who are subscribers to the Wiley InterScience publications site.

Laboratory testing for fibrinogen abnormalities

Fibrinogen is essential for the formation of a fibrin clot. Acquired and congenital disorders of fibrinogenmay result in decreased concentration or altered function of fibrinogen, often leading to an increased risk of bleeding. Routine coagulation testing and specialized laboratory investigations can guide diagnosis in patients suspected of having a fibrinogen abnormality. This article summarizes the types of laboratory assays that are used to assess fibrinogen disorders, and key abnormalities found in different types of fibrinogen disorders. Am. J. Hematol. 83:928–931, 2008. VVC 2008 Wiley-Liss, Inc.



The link to the full text for subscribers: 

 

Posted: Thursday, January 15, 2009

NASCOLA Member Publications

 
 

In accordance with the open access policies of the journal Thrombosis and Hemostasis, and with the permission of the publishers and authors, a PDF version of a publication can be posted to a website.  As such, we are pleased to offer the latest publication from NASCOLA members.  The original article, entitled, "Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practice" is published in: Thrombosis and Haemostasis 2009;101(1):178-184. The original article can be accessed on-line at: www.schattauer.de

Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practice

 

Posted: Thursday, November 20, 2008

2008 Coagulation/Hemostasis Technologist Award for Excellence

 

Every year, the Aniara Coagulation Hemostasis Technologist Award of Excellence (CHTAE) Committee recognizes a special coagulation technologist in North America.  The recipient is chosen by a volunteer committee of peers (technologists from the United States and Canada) from a pool of nominations received from the hemostasis community.

 

Ms. Kelly Townsend, from TriCore Reference Labs in Albuquerque, NM, USA, has been selected as the recipient of the Aniara-sponsored 2008 CHTAE award.

 

 

Kelly’s medical director and nominator, Dr. Kendall Crookston, MD, PhD, summarized Kelly’s wide range of responsibilities.  She is responsible for the operation of a large special coagulation laboratory in New Mexico and serves as a consultant for seventeen off-site affiliated hospitals and laboratories.  Dr. Crookston wrote that Kelly has “remarkable insight into quality issues, compliance, and meeting the needs of both physicians and patients.”  Kelly is also a volunteer faculty member at the University of New Mexico Department of Pathology and the Transfusion Medicine Fellowship Training program.

 

Kelly demonstrates the attributes that personify an excellent coagulation and hemostasis technologist.  The selection committee agreed that Kelly’s approachable nature and empathy, her knowledge base, as well as her commitment to provide excellent patient care and quality laboratory medicine, has lead her to become an essential team member for the provision of health care in New Mexico.  The 2008 CHTAE award is a tribute to Kelly’s strong leadership abilities and her contributions to the education of technologists, medical students, and residents in the area of hemostasis.

 

Congratulations Kelly!

 

Posted: Wednesday, September 10, 2008

NASCOLA is piloting new EQA on platelet disorders

 
After successful pilot EQA on platelet dense granule deficiency and LTA interpretation, NASCOLA has launched regular surveys for EQA on platelet dense granule deficiency, and a free, 2nd pilot EQA on interpretation of platelet aggregation studies. NASCOLA appreciates your support of these exercises and feedback from participants has been very positive. Karen Moffat presented on NASCOLA experiences with these EQA at the ISTH meeting in Boston 2009. Thank you for your support of these new exercises!

On behalf of the executive, Catherine Hayward, NASCOLA President
 

Updated: Monday, May 12, 2008

Posted: Tuesday, January 23, 2007

Invitation to join in NASCOLA's activities

 
NASCOLA welcomes increased and renewed membership involvement in activities. Please visit our Officers and Committees page to review our current Working Groups, and their membership and Chairs. To get involved, you are welcome to use the links below to contact the Chair of the Working Group that you would most like to get involved in, or if you want to contact our executive secretary to discuss other ways of helping out. We are open to suggestions on new activities! In response to the needs of members, NASCOLA launched a Platelet EQA Working Group in 2008 - your ideas matter!

Associate members are welcome to contact Beth Plumhoff, our Associate Member Liason, to share their ideas on NASCOLA activities.

The NASCOLA Executive welcomes your communication.

 

Posted: Monday, April 28, 2008

Opportunity for Member Trainees

 

The PT/EQA committee has several opportunities for trainee involvement in the analysis of NASCOLA data for the following analytes leading to potential publication.

 

APCR

Please contact Dr. Elizabeth VanCott, Massachusetts General Hospital

Email: evancott@partners.org

 

D-Dimer

Please contact Dr. Menaka Pai, Fellowship Program in Adult Hematology,McMaster University 

Email:  mpai@mcmaster.ca


Platelet Function Subcommittee

Please contact Dr Catherine Hayward, McMaster University

Email: haywrdc@mcmaster.ca

 

 

Posted: Tuesday, April 15, 2008

Announcement of a Platelet Type von Willebrand disease (PT-VWD)

 

Drs. Maha Othman and David Lillicrap at Queen's University in Kingston, Ontario (Canada) are inviting laboratories to participate in a molecular genetics study to investigate the occurrence of platelet type (PT) VWD among patients provisionally diagnosed as Type 2B VWD, based on clinical and laboratory data. The study involves analysis of blood samples, from consenting patients and with local institutional research ethics board review, as outlined in the following PDF document Platelet Type von Willebrand Disease Study which contains contact information for the investigators. The study description and contact information can also be accessed on the Queen's University website  PT-VWD Registry  NASCOLA endorses this effort and encourages your participation if you are able to do so.